Search company, investor...

Population Genetics Technologies

Founded Year



Series B | Alive

Total Raised


Last Raised

$5.7M | 11 yrs ago

About Population Genetics Technologies

Population Genetics Technologies (PGT) develops technologies that aim to transform the economic viability of performing large scale genetic population studies and allow the detection and characterization of rare allelic variants increasingly thought to play a major role in the development of many disease states.

Headquarters Location


CB22 3AQ,

United Kingdom

(+440) 122-349-7357

Missing: Population Genetics Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Population Genetics Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Population Genetics Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Population Genetics Technologies is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Population Genetics Technologies Patents

Population Genetics Technologies has filed 39 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • DNA
  • Genetics
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Genetics, DNA sequencing, DNA, Biotechnology


Application Date


Grant Date



Related Topics

Molecular biology, Genetics, DNA sequencing, DNA, Biotechnology



Latest Population Genetics Technologies News

Population Genetics Technologies Ltd Medical Equipment Deals and Alliances Profile Report Updated 07092018 Prices from USD $250

Sep 28, 2018

Population Genetics Technologies Ltd Medical Equipment Deals and Alliances Profile [Report Updated: 07092018] Prices from USD $250 06:18 EDT 28 Sep 2018 | BioPortfolio Reports Summary Population Genetics Technologies Ltd Population Genetics, a subsidiary of Agilent Technologies Inc is a biotechnology company. The company commercialize nucleic acid biochemistry tools and approaches. Its intellectual property assets include method for normalizing a nucleic acid sample, method for fragmenting a nucleic acid for sequencing , method for identifying minority variants in a sample, methods and compositions for isolating nucleic acid sequence variants, multiplexed analytical platform and others. The company currently markets certain intellectual property families within its portfolio, targeting companies in the molecular diagnostic and broader sequencing and life science tools sectors. Population Genetics is headquartered in Cambridge, the UK. Population Genetics Technologies Ltd Medical Equipment Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Medical eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Population Genetics Technologies Frequently Asked Questions (FAQ)

  • When was Population Genetics Technologies founded?

    Population Genetics Technologies was founded in 2005.

  • What is Population Genetics Technologies's latest funding round?

    Population Genetics Technologies's latest funding round is Series B.

  • How much did Population Genetics Technologies raise?

    Population Genetics Technologies raised a total of $18.3M.

  • Who are the investors of Population Genetics Technologies?

    Investors of Population Genetics Technologies include Auriga, Compass Genetics Investors, Wellcome Trust, Beringea, Syngenta Ventures and 3 more.

  • Who are Population Genetics Technologies's competitors?

    Competitors of Population Genetics Technologies include Gentronix Limited, Lycera, Echelon Biosciences, Promentis Pharmaceuticals, Kemp Proteins and 10 more.

Compare Population Genetics Technologies to Competitors


The bacteriophage vaccination technology originated at Moredun Research Institute when Dr. John March and Dr. Jason Clark were working on production of cheap, stable, efficient vaccines for use in developing countries.


Alzheimer's Disease is a modern curse that negates the many benefits from modern medicine and improved standards of hygiene and living. As the human population life-span is increased, a larger percentage of people will succumb to debilitating and distressing memory loss. Alzeim is dedicated to making available a natural plant alkaloid " Galanthamine (also widely called Galantamine) - that is proven to be a drug in the alleviation of memory-loss symptoms.nIt has few adverse side-effects and is currently extremely expensive to produce either from wild plants or by synthesis. By the application of research adding to its existing framework of knowledge, the company is establishing a new agri-industry in an upland region of Wales. Once production is adequate, it will make Galanthamine more widely available and affordable. Daffodils grown in the Black Mountains - helping Alzheimer's patientsnnGalanthamine has been known for some time as one of the few effective treatments for patients at certain stages of Alzheimer's Disease, having been produced in its natural form from plants found in the wild " principally in the Balkan region. This natural alkaloid is currently in short supply and because of the large number of potential patients (c. 700,000 currently in UK) is a very expensive treatment in total for a health provider to assume. In Scotland all patients who can benefit from it, and from related drugs, have access on prescription, but in England and Wales, the National Institute for Clinical Excellence (NICE) has decided to withdraw all anti-cholinesterase treatments from the National Health Service as regards new patients, because of the high total cost of branded medicines still subject to restrictive product licence. That decision has caused an outcry from sufferers and their families, and is being disputed in the High Court. It may not be resolved until after the drugs are able to be produced and sold in generic form. Nevertheless, global demand for Galanthamine is expanding rapidly. Alzeim expects to be able to provide much-needed extra quantities of the drug at lower prices thereby enabling many more patients to benefit from this treatment. Field trials, plant species and variety screening and laboratory extraction, purification and analysis work undertaken initially in co-operation with the IGER institute of University of Wales, Aberystwyth, indicated that a feasible route existed to produce Galanthamine economically in special regimes in parts of Mid-Wales. Since then, using mechanization under agronomic conditions, Alzeim has developed new production regimes with its own cultivars.nAmong other academic collaborations Alzeim is working on aspects of Galanthamine extraction and purification with the University of Manchester.

Active Pass Pharmaceuticals

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.


Opulus, Ltd. is a biotechnology company focused on the development of new measurement systems based on hyphenated Quartz Crystal Microbalance for molecular biology, drug discovery, and the development of new materials for drug delivery and cosmetic treatment based on high resolution visco-elastic kinetics and in-situ cytotoxicity.


Areta International was founded, with totally private financial support, by Dr. Maria Luisa Nolli in autumn 1999 as a spin-off of cell biology Laboratories of Lepetit Research Center, part of multinational companies, where she had a twenty years experience as scientist and team leader. nnThe company was born to cover the gap existing between the excellent basic research and the poor development of discoveries, with a view of helping customers to transform research projects in new potential biodrugs. nn nn

Biomedica Management

Biomedica Management Corporation is a Small Business Disadvantaged Company 8(a) certified by the Small Business Administration, operating in the field of the biomedical sciences and research & development. Biomedica signed a CRADA agreement with US Army Institute for Surgical Research to study an intracaviray hemostatic agent for use in the battlefield. The study was funded by TEDCO, and a second round of funding is assured by Johnson & Johnson.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.